Hepatocellular carcinoma explain as essay for 10 marks

Reading File

Finding Sources

Reading File

I now have comprehensive, high-quality content from Goldman-Cecil Medicine and Current Surgical Therapy. I have enough for a thorough 10-mark essay. Let me compose it now.

Hepatocellular Carcinoma (HCC)

Introduction

Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver, arising from malignant transformation of hepatocytes. It represents the third leading cause of cancer death worldwide, accounting for approximately 900,000 new cases and 830,000 deaths annually. Over 80% of cases occur in developing countries, though incidence is rising in developed nations as well, largely driven by the epidemic of nonalcoholic fatty liver disease and chronic hepatitis C. - Goldman-Cecil Medicine, p. 2063

Etiology and Risk Factors

HCC almost always arises in the setting of chronic liver disease and cirrhosis. The major risk factors include:

Chronic viral hepatitis - Hepatitis B virus (HBV) and Hepatitis C virus (HCV) together account for the majority of cases globally. HBV-associated HCC is unique in that it can develop even without prior cirrhosis due to direct viral DNA integration into the host genome.
Alcohol-related liver disease - Chronic alcohol use leads to cirrhosis, a strong precursor to HCC.
Non-alcoholic fatty liver disease (NAFLD) / non-alcoholic steatohepatitis (NASH) - An increasingly important cause, especially in Western populations.
Aflatoxin B1 exposure - A mycotoxin produced by Aspergillus species contaminating poorly stored grains; a major risk factor in sub-Saharan Africa and Southeast Asia, often acting synergistically with HBV.
Hereditary conditions - Hemochromatosis, Wilson's disease, alpha-1 antitrypsin deficiency, and glycogen storage diseases predispose to HCC.
Cirrhosis from any cause - Annual HCC incidence in cirrhotic patients is 1-5%.

A rare subtype, fibrolamellar HCC, occurs in younger patients without pre-existing liver disease or cirrhosis and carries a distinct prognosis. - Current Surgical Therapy 14e, p. 418

Pathobiology

HCC develops through a multi-step process. Chronic liver injury triggers repeated cycles of inflammation, hepatocyte necrosis, regenerative proliferation, and accumulation of genetic damage. Key molecular events include:

TERT promoter mutations - activation of telomerase reverse transcriptase, seen in ~45% of cases
TP53 inactivation - loss of tumor suppressor function, in ~30% of cases
CTNNB1 (β-catenin) activation - oncogene activation, in ~25% of cases
Dysregulation of the Wnt signaling pathway, cell cycle control, and chromatin-remodeling pathways

In HBV-associated HCC, the virus directly integrates its DNA into specific host genome loci (particularly the TERT promoter), providing an additional oncogenic mechanism independent of cirrhosis. - Goldman-Cecil Medicine, p. 2064

The progression from normal liver to HCC follows the sequence: chronic hepatitis → fibrosis → cirrhosis → dysplastic nodule → early HCC → advanced HCC.

Clinical Features

HCC may be detected at an asymptomatic stage through surveillance programs in at-risk patients, or may present with:

Right upper quadrant pain or a palpable hepatic mass
Jaundice (from biliary obstruction or liver failure)
Ascites, variceal bleeding, or worsening portal hypertension in cirrhotic patients
Constitutional symptoms - weight loss, anorexia, fatigue, fever, and night sweats
Decompensation of known cirrhosis - a sudden deterioration should raise suspicion for HCC

Paraneoplastic manifestations are uncommon but include hypercalcemia of malignancy and erythrocytosis due to ectopic erythropoietin production. Metastatic spread occurs most commonly to lungs, peritoneum, bone, adrenal glands, spleen, and brain. - Goldman-Cecil Medicine, p. 2065

Diagnosis

Serum Markers

Alpha-fetoprotein (AFP) is the primary tumor marker. Levels >400 ng/mL in the context of a liver mass are highly suggestive of HCC, though AFP can be normal in up to 40% of cases.
CA 19-9 and CEA may be checked if the diagnosis is uncertain to exclude other primaries.

Imaging

Contrast-enhanced CT or MRI of the abdomen is the diagnostic cornerstone. The hallmark imaging pattern is:

Arterial phase hyperenhancement (due to neovascularization)
Portal venous phase "washout" appearance

This pattern is considered diagnostic of HCC without biopsy in the context of known cirrhosis or chronic liver disease. The Liver Imaging Reporting and Data System (LI-RADS) standardizes reporting; a LI-RADS 5 designation is diagnostic for HCC. - Current Surgical Therapy 14e, p. 418

Biopsy

Tissue biopsy is generally not required when imaging is diagnostic. It is reserved for cases where imaging is inconclusive or when molecular profiling is needed to guide systemic therapy.

Staging

Multiple staging systems are used because HCC is unique in that both tumor extent and the degree of underlying liver disease influence prognosis and treatment decisions:

System	What It Incorporates
AJCC	Tumor-node-metastasis (TNM)
Barcelona Clinic Liver Cancer (BCLC)	Tumor burden + liver function + performance status; guides treatment allocation
Okuda	Tumor size + ascites + albumin + bilirubin
Child-Turcotte-Pugh (CTP)	Liver function (bilirubin, albumin, PT, ascites, encephalopathy)

BCLC is the most widely used system and classifies patients as Very Early (0), Early (A), Intermediate (B), Advanced (C), or Terminal (D). - Current Surgical Therapy 14e, p. 418

Treatment

Management must balance tumor control with the management of underlying liver disease.

Curative Options

Liver Transplantation - The preferred curative option for patients with advanced cirrhosis and limited HCC (within Milan criteria: single lesion ≤5 cm, or up to 3 lesions each ≤3 cm, no vascular invasion, no extrahepatic spread). It addresses both the tumor and the cirrhotic "field defect," eliminating risk of new HCC from the diseased liver. Limitations include organ availability and immunosuppression risks.
Surgical Resection - Indicated for patients with limited or no underlying cirrhosis (Child-Pugh A without portal hypertension). Anatomic resections aligned with portal territories (segmentectomy, sectionectomy) are preferred due to HCC's tendency to spread along portal venous tributaries. Perioperative mortality is <5% in Child-Pugh A patients but rises substantially in Child-Pugh B/C. - Current Surgical Therapy 14e, p. 418
Thermal Ablation (RFA/Microwave) - For patients unfit for surgery, ablation of small HCC (<2-3 cm) achieves long-term outcomes comparable to surgical resection with lower morbidity, based on multiple randomized trials.

Locoregional Therapies (Bridge or Palliative)

Transarterial Chemoembolization (TACE) - Delivers cytotoxic agents directly into the hepatic artery supplying the tumor, combined with arterial embolization. Used for intermediate-stage (BCLC-B) disease not amenable to curative treatment, or as a bridge to transplantation.
Transarterial Radioembolization (TARE / Yttrium-90) - Microspheres loaded with Y-90 are delivered intra-arterially, providing local radiation therapy.
Bland embolization (HAE) - Embolization without chemotherapy, reserved for cases where TACE is not appropriate.

Systemic Therapy

For advanced HCC (BCLC-C/D) with extrahepatic spread or vascular invasion:

Sorafenib and lenvatinib (multikinase inhibitors) are approved first-line agents that target VEGF and other growth factor receptors, prolonging survival.
Regorafenib, cabozantinib, ramucirumab are second-line multikinase inhibitors.
Immune checkpoint inhibitors - Nivolumab (anti-PD-1) and pembrolizumab (anti-PD-1), alone or combined with ipilimumab (anti-CTLA-4), provide durable tumor responses. The combination of atezolizumab + bevacizumab (anti-PD-L1 + anti-VEGF) is now a preferred first-line standard. - Goldman-Cecil Medicine, p. 2063

Surveillance and Prevention

High-risk patients (cirrhosis of any cause, chronic HBV carriers) should undergo surveillance every 6 months with liver ultrasound and serum AFP. This enables detection at early, potentially curable stages. Prevention includes:

HBV vaccination - highly effective; has reduced HCC incidence in regions of high endemicity (e.g., Taiwan)
Antiviral therapy - HBV suppression with nucleos(t)ide analogues and HCV eradication with direct-acting antivirals reduce HCC risk substantially
Alcohol abstinence and treatment of metabolic liver disease

Prognosis

Prognosis is strongly stage-dependent. Early-stage HCC treated with curative intent (transplant, resection, ablation) has 5-year survival rates of 50-70%. Intermediate-stage disease managed with TACE has a median survival of 16-24 months. Advanced/terminal disease managed with systemic therapy has a median overall survival of approximately 12-18 months. The presence of portal vein thrombosis, extrahepatic metastases, and poor liver reserve (Child-Pugh C) all confer poor prognosis.

Conclusion

HCC is a complex malignancy arising at the intersection of chronic liver disease and carcinogenesis. Its management requires a multidisciplinary approach integrating hepatology, oncology, radiology, and transplant surgery. Early detection through surveillance of high-risk populations remains the most effective strategy to improve outcomes. Advances in systemic immunotherapy and targeted agents have transformed the landscape for advanced disease, offering meaningful survival benefit where few options previously existed.

Sources: Goldman-Cecil Medicine International Edition; Current Surgical Therapy, 14th Edition; Tietz Textbook of Laboratory Medicine, 7th Edition

This is a shared conversation. Sign in to Orris to start your own chat.